Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment [Yahoo! Finance]
Clene Inc. (CLNN)
Company Research
Source: Yahoo! Finance
Significant improvements in both vision and cognition, sustained over three years, were reported with CNM-Au8 treatment in results from the long-term open-label extension ("LTE") of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis Michael Barnett, a key clinical advisor, hailed the results, observed long term and over and above background therapy. as "unprecedented" A drug that may halt MS disease progression or improve function on top of standard-of-care MS therapies would represent a significant milestone in drug development for this disease Clene will present the full clinical results for the LTE at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum scheduled for February 29 through March 2, 2024, in West Palm Beach, Florida Clene (NASDAQ: CLNN) and its wholly-owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington [Yahoo! Finance]Yahoo! Finance
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob EtheringtonGlobeNewswire
- ‘Liquid gold' could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit' [FOX News]FOX News
- Bullish Clene Insiders Loaded Up On US$9.58m Of Stock [Yahoo! Finance]Yahoo! Finance
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
CLNN
Earnings
- 11/7/23 - Beat
CLNN
Sec Filings
- 5/1/24 - Form 4
- 4/26/24 - Form 8-K
- 4/17/24 - Form ARS
- CLNN's page on the SEC website